AU2007313472B2 - Population scale HLA-typing and uses thereof - Google Patents
Population scale HLA-typing and uses thereof Download PDFInfo
- Publication number
- AU2007313472B2 AU2007313472B2 AU2007313472A AU2007313472A AU2007313472B2 AU 2007313472 B2 AU2007313472 B2 AU 2007313472B2 AU 2007313472 A AU2007313472 A AU 2007313472A AU 2007313472 A AU2007313472 A AU 2007313472A AU 2007313472 B2 AU2007313472 B2 AU 2007313472B2
- Authority
- AU
- Australia
- Prior art keywords
- hla
- dna
- pcr
- probes
- lane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000523 sample Substances 0.000 claims abstract description 162
- 238000002493 microarray Methods 0.000 claims abstract description 73
- 238000009396 hybridization Methods 0.000 claims abstract description 64
- 239000002773 nucleotide Substances 0.000 claims abstract description 21
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 20
- 239000000758 substrate Substances 0.000 claims description 11
- 125000002091 cationic group Chemical group 0.000 claims description 10
- 229940104230 thymidine Drugs 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 4
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 3
- 229910001887 tin oxide Inorganic materials 0.000 claims description 3
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 108700028369 Alleles Proteins 0.000 abstract description 84
- 238000000034 method Methods 0.000 abstract description 64
- 238000003205 genotyping method Methods 0.000 abstract description 9
- 108020004414 DNA Proteins 0.000 description 80
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 54
- 108010058607 HLA-B Antigens Proteins 0.000 description 40
- 102000006390 HLA-B Antigens Human genes 0.000 description 40
- 239000000047 product Substances 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 31
- 229960002685 biotin Drugs 0.000 description 27
- 235000020958 biotin Nutrition 0.000 description 27
- 239000011616 biotin Substances 0.000 description 27
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 23
- 108010075704 HLA-A Antigens Proteins 0.000 description 22
- 108091093088 Amplicon Proteins 0.000 description 20
- 102000054765 polymorphisms of proteins Human genes 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 16
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 16
- 239000002751 oligonucleotide probe Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 101710113436 GTPase KRas Proteins 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 108700024394 Exon Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000003321 amplification Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000000274 adsorptive effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003066 decision tree Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002324 mouth wash Substances 0.000 description 5
- 229940051866 mouthwash Drugs 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 229920004934 Dacron® Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 101100108292 Caenorhabditis elegans aex-2 gene Proteins 0.000 description 2
- 101100182883 Caenorhabditis elegans aex-3 gene Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 108700005092 MHC Class II Genes Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- IXZONVAEGFOVSF-UHFFFAOYSA-N 2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3H)-quinazolinone Chemical compound OP(O)(=O)OC1=CC=C(Cl)C=C1C1=NC(=O)C2=CC(Cl)=CC=C2N1 IXZONVAEGFOVSF-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical class [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 description 1
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 1
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 1
- 101100395311 Homo sapiens HLA-B gene Proteins 0.000 description 1
- 101100395312 Homo sapiens HLA-C gene Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000006012 Parham cyclization reaction Methods 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 101000737296 Pisum sativum Chlorophyll a-b binding protein AB96 Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- -1 SCO Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013273684A AU2013273684A1 (en) | 2006-02-27 | 2013-12-18 | Population scale hla-typing and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77707806P | 2006-02-27 | 2006-02-27 | |
| US60/777,078 | 2006-02-27 | ||
| PCT/US2007/005121 WO2008048355A2 (en) | 2006-02-27 | 2007-02-27 | Population scale hla-typing and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013273684A Division AU2013273684A1 (en) | 2006-02-27 | 2013-12-18 | Population scale hla-typing and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007313472A1 AU2007313472A1 (en) | 2008-04-24 |
| AU2007313472B2 true AU2007313472B2 (en) | 2014-01-16 |
Family
ID=39314565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007313472A Ceased AU2007313472B2 (en) | 2006-02-27 | 2007-02-27 | Population scale HLA-typing and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7667026B2 (enExample) |
| EP (1) | EP1991558B1 (enExample) |
| JP (1) | JP2009528060A (enExample) |
| KR (1) | KR20080100461A (enExample) |
| AU (1) | AU2007313472B2 (enExample) |
| CA (1) | CA2643771A1 (enExample) |
| NZ (2) | NZ571513A (enExample) |
| SG (1) | SG172644A1 (enExample) |
| WO (1) | WO2008048355A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| CA2643771A1 (en) * | 2006-02-27 | 2008-04-24 | Michael E. Hogan | Population scale hla-typing and uses thereof |
| DE102009035286A1 (de) * | 2009-07-30 | 2011-02-10 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Darstellung computertomographischer Untersuchungsdaten eines Untersuchungsobjektes |
| US8771951B2 (en) | 2009-11-16 | 2014-07-08 | Genomics Usa, Inc. | Methods for PCR and HLA typing using raw blood |
| US8969254B2 (en) | 2010-12-16 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
| JP6233022B2 (ja) * | 2011-12-28 | 2017-11-22 | 凸版印刷株式会社 | Ｈｌａ−ａ＊２４グループの判定方法 |
| HUP1200622A2 (en) * | 2012-10-30 | 2014-05-28 | Budapesti Mueszaki Es Gazdasagtudomanyi Egyetem | Method and computer program product for genotype classification |
| WO2014160046A1 (en) * | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | A method for detecting mutations in single cells or single molecules |
| EP2997037B1 (en) * | 2013-05-14 | 2018-11-21 | Genomics USA, Inc. | Use of a composition for entrapping a protein on a surface |
| ES2791415T3 (es) * | 2015-12-01 | 2020-11-04 | Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P | Método para diagnosticar miocardiopatías |
| US10612075B2 (en) * | 2015-12-28 | 2020-04-07 | PathogenDX Inc | Microarray based multiplex pathogen analysis and uses thereof |
| US11542498B2 (en) * | 2015-12-28 | 2023-01-03 | Pathogendx, Inc. | Microarray based multiplex pathogen analysis and uses thereof |
| KR102673550B1 (ko) * | 2017-11-23 | 2024-06-12 | (주)오상헬스케어 | 실시간 중합 효소 연쇄 반응을 이용한 ｈｌａ 대립유전자 검사 키트 |
| CN114423874A (zh) * | 2019-07-05 | 2022-04-29 | 英特莱克森有限责任公司 | 个体hla分型的确定方法及其作为预测因子、靶基因和治疗剂的用途 |
| KR102511162B1 (ko) * | 2021-11-01 | 2023-03-20 | 대한민국 | 한국인 특이적 snp 정보 및 최적화된 파이프라인을 이용한 hla-drb1 유전자형 분석 방법 |
| KR102511161B1 (ko) * | 2021-11-01 | 2023-03-20 | 대한민국 | 한국인 특이적 snp 정보 및 최적화된 파이프라인을 이용한 hla-a 유전자형 분석 방법 |
| KR102543976B1 (ko) * | 2021-11-01 | 2023-06-15 | 대한민국 | 한국인 특이적 snp 정보 및 최적화된 파이프라인을 이용한 hla-b 유전자형 분석 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061795A2 (en) * | 1999-04-09 | 2000-10-19 | Innogenetics N.V. | Method for the amplification of hla class i alleles |
| WO2000079006A1 (en) * | 1999-06-17 | 2000-12-28 | Fred Hutchinson Cancer Research Center | Oligonucleotide arrays for high resolution hla typing |
| WO2005042764A2 (en) * | 2003-10-28 | 2005-05-12 | Dynal Biotech Llc | Primers, methods and kits for amplifying or detecting human leukocyte antigen alleles |
| US20050260662A1 (en) * | 2004-05-20 | 2005-11-24 | Jiacheng Yang | Genotyping of multiple loci with PCR for different loci amplification at different temperatures |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582788A (en) * | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US5567809A (en) * | 1986-03-13 | 1996-10-22 | Hoffmann-La Roche Inc. | Methods and reagents for HLA DRbeta DNA typing |
| AU6657996A (en) * | 1995-07-18 | 1997-02-18 | Guido Krupp | Ribozymes for the selective inhibition of expression by mhc llele genes, and drugs containing such ribozymes |
| WO2000031295A1 (en) * | 1998-11-26 | 2000-06-02 | Shionogi & Co., Ltd. | Method for distinguishing hla class i allele type |
| AU6093300A (en) * | 1999-07-14 | 2001-02-05 | Genometrix Genomics Incorporated | Arrays comprising non-covalently associated nucleic acid probes and methods for making and using them |
| US6670124B1 (en) * | 1999-12-20 | 2003-12-30 | Stemcyte, Inc. | High throughput methods of HLA typing |
| CA2643771A1 (en) * | 2006-02-27 | 2008-04-24 | Michael E. Hogan | Population scale hla-typing and uses thereof |
-
2007
- 2007-02-27 CA CA002643771A patent/CA2643771A1/en not_active Abandoned
- 2007-02-27 KR KR1020087023410A patent/KR20080100461A/ko not_active Ceased
- 2007-02-27 US US11/711,561 patent/US7667026B2/en not_active Expired - Fee Related
- 2007-02-27 EP EP07861253.8A patent/EP1991558B1/en not_active Not-in-force
- 2007-02-27 WO PCT/US2007/005121 patent/WO2008048355A2/en not_active Ceased
- 2007-02-27 NZ NZ571513A patent/NZ571513A/en not_active IP Right Cessation
- 2007-02-27 AU AU2007313472A patent/AU2007313472B2/en not_active Ceased
- 2007-02-27 SG SG2011038734A patent/SG172644A1/en unknown
- 2007-02-27 JP JP2008557340A patent/JP2009528060A/ja active Pending
-
2010
- 2010-02-18 US US12/660,002 patent/US8183360B2/en not_active Expired - Fee Related
-
2011
- 2011-12-19 NZ NZ597200A patent/NZ597200A/xx not_active IP Right Cessation
-
2012
- 2012-05-21 US US13/476,774 patent/US8575325B2/en not_active Expired - Fee Related
-
2013
- 2013-11-04 US US14/070,819 patent/US20140135231A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061795A2 (en) * | 1999-04-09 | 2000-10-19 | Innogenetics N.V. | Method for the amplification of hla class i alleles |
| US20020197613A1 (en) * | 1999-04-09 | 2002-12-26 | Canck Ilse De | Method for the amplification of HLA class I alleles |
| WO2000079006A1 (en) * | 1999-06-17 | 2000-12-28 | Fred Hutchinson Cancer Research Center | Oligonucleotide arrays for high resolution hla typing |
| WO2005042764A2 (en) * | 2003-10-28 | 2005-05-12 | Dynal Biotech Llc | Primers, methods and kits for amplifying or detecting human leukocyte antigen alleles |
| US20050260662A1 (en) * | 2004-05-20 | 2005-11-24 | Jiacheng Yang | Genotyping of multiple loci with PCR for different loci amplification at different temperatures |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008048355A3 (en) | 2008-11-13 |
| EP1991558B1 (en) | 2015-11-18 |
| CA2643771A1 (en) | 2008-04-24 |
| JP2009528060A (ja) | 2009-08-06 |
| WO2008048355A2 (en) | 2008-04-24 |
| US20070298425A1 (en) | 2007-12-27 |
| SG172644A1 (en) | 2011-07-28 |
| NZ597200A (en) | 2013-06-28 |
| US8575325B2 (en) | 2013-11-05 |
| US7667026B2 (en) | 2010-02-23 |
| US8183360B2 (en) | 2012-05-22 |
| EP1991558A4 (en) | 2009-11-04 |
| US20100279889A1 (en) | 2010-11-04 |
| US20140135231A1 (en) | 2014-05-15 |
| AU2007313472A1 (en) | 2008-04-24 |
| KR20080100461A (ko) | 2008-11-18 |
| EP1991558A2 (en) | 2008-11-19 |
| NZ571513A (en) | 2012-02-24 |
| US20120302457A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007313472B2 (en) | Population scale HLA-typing and uses thereof | |
| US7300755B1 (en) | Methods for haplotyping genomic DNA | |
| JP5968879B2 (ja) | Ｄｎａ分子タグ技術及びｄｎａ不完全断片化技術に基づいたｐｃｒシークエンシング法及びそれを用いたｈｌａ遺伝子タイピング法 | |
| US9562269B2 (en) | Haplotying of HLA loci with ultra-deep shotgun sequencing | |
| US8969254B2 (en) | Oligonucleotide array for tissue typing | |
| Liu et al. | Extended blood group molecular typing and next-generation sequencing | |
| US20090099035A1 (en) | Oligonucleotide arrays for high resolution hla typing | |
| JP2014507164A (ja) | ハプロタイプ決定のための方法およびシステム | |
| JP2009528060A5 (enExample) | ||
| US8343720B2 (en) | Methods and probes for identifying a nucleotide sequence | |
| JP3384806B2 (ja) | Ｈｌａ−ｄｒ型別判定の実施を可能にするプローブ系および該プローブを用いる型別判定法 | |
| WO2007056904A1 (en) | Microarrays for genotyping and methods of use | |
| AU2013273684A1 (en) | Population scale hla-typing and uses thereof | |
| US20050032102A1 (en) | Mapping genomic rearrangements | |
| KR100892253B1 (ko) | 인간 미토콘드리아 ｄｎａ의 변이 판별 방법과 변이 판별용폴리뉴클레오티드 프로브, ｄｎａ 칩 및 키트 | |
| KR20220047180A (ko) | 청고병 저항성 고추 판별용 분자마커 및 이의 용도 | |
| Kolman | Progress and Perspectives on Ancient DNA Technology | |
| und zytogenetische Redaktion et al. | Translation of next-generation sequencing (NGS) into molecular diagnostics | |
| WO2004044242A1 (en) | Polymorphism assay | |
| JP2011050377A (ja) | 新規ｈｌａ−ｄｒｂ１遺伝子およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |